Figure 5

RocA selectively diminishes the viability and migration of KRAS-mutated pancreatic cancer cells. A. Viability of DMSO- and RocA-treated AsPC-1 and Panc-1 cells. Values are the means ± SD of triplicate samples, *P < 0.01. B. Viability of DMSO- and RocA-treated Hs 578Bst and L02 cells. Values are the means ± SD of triplicate samples, *P < 0.01. C. Transwell migration assays of AsPC-1 and Panc-1 cells treated with RocA (50 or 100 nM). The plot shows the quantification of cells that passed through the filters relative to DMSO that was set to 100%. Values are the means ± SD of triplicate samples, *P < 0.01. Scale bars, 25 μm. D. Effect of RocA on pancreatic cancer metastasis in an orthotopic xenograft model. AsPC-1 cells were orthotopically injected into the pancreas of mice (n = 6) as described in the Methods. At 1 week post-implantation, RocA (5.0 mg/kg, n = 3) or the vehicle (1% DMSO in olive oil, n = 3) was administrated via daily intraperitoneal injection for 4 weeks. Then, the lungs and livers of mice were collected and processed for H&E staining. The number of tumor foci was counted in the lungs and livers of sacrificed mice. Arrows indicate tumor foci. T, tumor. Values are the means ± SD of triplicate samples, *P < 0.01. Scale bars, 50 μm.